<DOC>
	<DOC>NCT00899847</DOC>
	<brief_summary>To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.</brief_summary>
	<brief_title>Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI &amp; ATG</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>3.1.1 Stage IIIII multiple myeloma or have progression after initial treatment of Stage I disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included. 3.1.2 Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center. 3.1.3 Age &gt; 18 years and &lt;= 75 years. 3.1.4 Karnofsky Performance Status &gt; 70%. 3.1.5 Corrected DLCO &gt; 60% 3.1.6 Left ventricle ejection fraction (LVEF) &gt; 50%. 3.1.7 ALT and AST must be &lt;= 2X normal. Total bilirubin &lt;= 2 mg/dL unless hemolysis or Gilbert's disease. 3.1.8 Estimated creatinine clearance &gt; 50 ml/min. 3.1.9 Have a related or unrelated HLAidentical donor or one antigen/allele mismatched in HLAA, B, C or DRB1. 3.1.10 Signed informed consent. 3.3 Donor Evaluation Inclusion Criteria 3.3.1 Age &gt;=17. 3.3.2 HIV seronegative 3.3.3 Donor must be capable of giving signed, informed consent 3.3.4 No contraindication to the administration of GCSF 3.3.5 Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate. 3.2.1 Prior allogeneic hematopoietic cell transplantation. 3.2.2 Uncontrolled active infection. 3.2.4 Uncontrolled congestive heart failure or angina. 3.2.5 Pregnancy or nursing patients will be excluded from the study. 3.2.6 Those who are HIVpositive will be excluded from the study due to high risk of lethal infection after hematopoietic cell transplantation. 3.4 Donor Evaluation Exclusion Criteria 3.4.1 Serious medical or psychological illness. 3.4.2 Pregnant or lactating women are not eligible 3.4.3 Prior malignancies within the last 5 years except for nonmelanoma skin cancers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>